On August 22, Guangxi CDC announced that the Guangxi Zhuang Autonomous Region Disease Prevention and Control Center will conduct a phase III clinical trial of the HPV vaccine for men in September. The trial will involve a domestically produced nine-valent vaccine and will follow up with 500 participants over six years. Many netizens are looking forward to the possibility of men receiving the human papillomavirus (HPV) vaccine domestically.
Many netizens are looking forward to the possibility of men receiving the human papillomavirus (HPV) vaccine domestically. On August 25, several clinical experts stated in interviews that from the perspective of herd immunity and disease prevention, it is very necessary for men to receive the HPV vaccine. After the verification of indications in the country, the vaccination of men with the HPV vaccine will inevitably be opened up.
It is reported that human papillomavirus (HPV) is an extremely common virus worldwide, primarily transmitted through sexual contact, and is one of the most common pathogens of sexually transmitted diseases. HPV is also recognized as one of the four main carcinogenic pathogens in the world. In men, HPV infection can lead to genital warts such as condylomata acuminata, infertility, and various tumors. Existing research has shown that HPV is associated with almost all genital warts, over 90% of cervical cancer, over 60% of anal cancer, and around 70% of oropharyngeal cancer. Vaccination with the HPV vaccine (commonly referred to as the “cervical cancer vaccine” in the market) is the most effective way to prevent HPV infection and can effectively prevent condylomata acuminata, genital cancer, cervical cancer, oropharyngeal cancer, laryngeal cancer, etc., while also reducing the infection and transmission of HPV between sexual partners.
This article is compiled from various sources including China News Service, People’s Daily Health Client, and Guangxi CDC.
(Source: This article is compiled by Jimu News)
